vs
Side-by-side financial comparison of Foghorn Therapeutics Inc. (FHTX) and SR Bancorp, Inc. (SRBK). Click either name above to swap in a different company.
Foghorn Therapeutics Inc. is the larger business by last-quarter revenue ($9.2M vs $8.4M, roughly 1.1× SR Bancorp, Inc.). SR Bancorp, Inc. runs the higher net margin — 10.0% vs -234.3%, a 244.2% gap on every dollar of revenue. On growth, Foghorn Therapeutics Inc. posted the faster year-over-year revenue change (223.8% vs 6.4%). Over the past eight quarters, Foghorn Therapeutics Inc.'s revenue compounded faster (35.3% CAGR vs -2.4%).
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.
SR Bancorp Inc. is a regional bank holding company based in the United States. It offers a full range of consumer and commercial banking services including deposit products, personal loans, mortgage lending, small business financing, and commercial credit solutions, primarily serving local communities and small to mid-sized enterprises in its operating areas.
FHTX vs SRBK — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $9.2M | $8.4M |
| Net Profit | $-21.7M | $834.0K |
| Gross Margin | — | — |
| Operating Margin | -258.2% | 13.0% |
| Net Margin | -234.3% | 10.0% |
| Revenue YoY | 223.8% | 6.4% |
| Net Profit YoY | -11.1% | -18.3% |
| EPS (diluted) | $-0.35 | $0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.2M | $8.4M | ||
| Q3 25 | $8.2M | $8.2M | ||
| Q2 25 | $7.6M | $7.6M | ||
| Q1 25 | $6.0M | $7.7M | ||
| Q4 24 | $2.9M | $7.9M | ||
| Q3 24 | $7.8M | $8.4M | ||
| Q2 24 | $6.9M | $7.9M | ||
| Q1 24 | $5.0M | $8.8M |
| Q4 25 | $-21.7M | $834.0K | ||
| Q3 25 | $-15.8M | $693.0K | ||
| Q2 25 | $-17.9M | $2.2M | ||
| Q1 25 | $-18.8M | $537.0K | ||
| Q4 24 | $-19.5M | $1.0M | ||
| Q3 24 | $-19.1M | $1.4M | ||
| Q2 24 | $-23.0M | $-3.0M | ||
| Q1 24 | $-25.0M | $1.1M |
| Q4 25 | -258.2% | 13.0% | ||
| Q3 25 | -226.9% | 11.0% | ||
| Q2 25 | -279.2% | 32.1% | ||
| Q1 25 | -385.0% | 8.1% | ||
| Q4 24 | -840.5% | 17.1% | ||
| Q3 24 | -305.5% | 20.6% | ||
| Q2 24 | -386.6% | -34.0% | ||
| Q1 24 | -558.3% | 15.4% |
| Q4 25 | -234.3% | 10.0% | ||
| Q3 25 | -194.4% | 8.5% | ||
| Q2 25 | -237.3% | 29.2% | ||
| Q1 25 | -316.4% | 7.0% | ||
| Q4 24 | -682.9% | 13.0% | ||
| Q3 24 | -244.9% | 16.3% | ||
| Q2 24 | -333.6% | -38.2% | ||
| Q1 24 | -495.4% | 12.1% |
| Q4 25 | $-0.35 | $0.11 | ||
| Q3 25 | $-0.25 | $0.09 | ||
| Q2 25 | $-0.28 | $0.27 | ||
| Q1 25 | $-0.30 | $0.06 | ||
| Q4 24 | $-0.23 | $0.12 | ||
| Q3 24 | $-0.31 | $0.16 | ||
| Q2 24 | $-0.45 | $8.14 | ||
| Q1 24 | $-0.59 | $0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.9M | $81.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-108.5M | $188.5M |
| Total Assets | $198.1M | $1.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.9M | $81.8M | ||
| Q3 25 | $89.3M | $58.3M | ||
| Q2 25 | $72.6M | $57.8M | ||
| Q1 25 | $61.0M | $62.2M | ||
| Q4 24 | $55.5M | $53.4M | ||
| Q3 24 | $57.7M | $47.3M | ||
| Q2 24 | $138.9M | $45.9M | ||
| Q1 24 | $79.3M | $72.5M |
| Q4 25 | $-108.5M | $188.5M | ||
| Q3 25 | $-89.7M | $191.9M | ||
| Q2 25 | $-76.7M | $193.8M | ||
| Q1 25 | $-61.7M | $195.1M | ||
| Q4 24 | $-45.5M | $198.1M | ||
| Q3 24 | $-28.3M | $200.5M | ||
| Q2 24 | $-14.3M | $199.5M | ||
| Q1 24 | $-97.5M | $199.3M |
| Q4 25 | $198.1M | $1.1B | ||
| Q3 25 | $205.0M | $1.1B | ||
| Q2 25 | $226.2M | $1.1B | ||
| Q1 25 | $258.7M | $1.1B | ||
| Q4 24 | $284.0M | $1.1B | ||
| Q3 24 | $308.4M | $1.1B | ||
| Q2 24 | $328.6M | $1.0B | ||
| Q1 24 | $255.0M | $1.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-22.3M | $3.6M |
| Free Cash FlowOCF − Capex | — | $3.1M |
| FCF MarginFCF / Revenue | — | 37.0% |
| Capex IntensityCapex / Revenue | 0.0% | 5.9% |
| Cash ConversionOCF / Net Profit | — | 4.31× |
| TTM Free Cash FlowTrailing 4 quarters | — | $11.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-22.3M | $3.6M | ||
| Q3 25 | $-18.9M | $1.2M | ||
| Q2 25 | $-21.0M | $4.7M | ||
| Q1 25 | $-24.0M | $2.6M | ||
| Q4 24 | $-24.5M | $-1.4M | ||
| Q3 24 | $-21.0M | $1.8M | ||
| Q2 24 | $-25.5M | $-1.7M | ||
| Q1 24 | $-29.3M | $-3.9M |
| Q4 25 | — | $3.1M | ||
| Q3 25 | — | $1.1M | ||
| Q2 25 | $-21.0M | $4.2M | ||
| Q1 25 | $-24.0M | $2.5M | ||
| Q4 24 | $-25.0M | $-1.5M | ||
| Q3 24 | $-21.3M | $1.7M | ||
| Q2 24 | $-25.6M | $-2.8M | ||
| Q1 24 | $-29.4M | $-4.0M |
| Q4 25 | — | 37.0% | ||
| Q3 25 | — | 14.0% | ||
| Q2 25 | -278.2% | 55.9% | ||
| Q1 25 | -403.2% | 32.3% | ||
| Q4 24 | -875.3% | -19.5% | ||
| Q3 24 | -273.0% | 20.3% | ||
| Q2 24 | -371.0% | -35.8% | ||
| Q1 24 | -583.1% | -45.2% |
| Q4 25 | 0.0% | 5.9% | ||
| Q3 25 | 0.0% | 0.9% | ||
| Q2 25 | 0.3% | 5.7% | ||
| Q1 25 | 0.5% | 1.0% | ||
| Q4 24 | 16.8% | 1.3% | ||
| Q3 24 | 4.0% | 1.0% | ||
| Q2 24 | 0.2% | 13.9% | ||
| Q1 24 | 2.0% | 0.5% |
| Q4 25 | — | 4.31× | ||
| Q3 25 | — | 1.76× | ||
| Q2 25 | — | 2.11× | ||
| Q1 25 | — | 4.79× | ||
| Q4 24 | — | -1.40× | ||
| Q3 24 | — | 1.31× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -3.69× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
